IMCI Pharmaceuticals
A Safer & Healthier Alternative to Consume Medicinal Cannabis

Medicinal cannabis is a proven treatment option for chronic pain, which has been approved by various national regulators across the globe. The most common way to consume it is through smoking. Smoking is a nonstandardized way to consume a medicinal product, together with its adverse side effects and long-term harmful hazards, it casts a shadow over the benefits of using cannabis medication and its attached social stigma.

IMCI has pioneered a better alternative to intake cannabis for therapeutic uses. Its iCann medicinal cannabis pharma-grade products, can deliver precise and effective doses with an easy-to-use administration technique, suitable for any patient population at any time and place.

“Our effective and patient-friendly products are reinventing the medicinal cannabis therapy space by meeting pharma standards, improving patient compliance and their quality of life. We foresee a surge in the number of patients using cannabis in a hazard-free and cost-effective manner,” says Alon Hershkovitz, founder and CEO of IMCI Pharmaceuticals.

At the heart of IMCI’s innovative cannabis products,is a proven platform technology for its safety and efficacy, by human clinical study, together with its pharmacology experts with decades of experience in drug discovery, medical device development, and marketing.

Inspired by the mission to overcome the challenges in administering medicinal cannabis, Alon Hershkovitz and Avi Yakobovich, pre-eminent thought leaders and avid entrepreneurs, set the foundation stone of IMCI.

iCann technology combines three elements—active pharmaceutical ingredients (API), innovative formulation, and delivery systems. Each product comprisesof unique cannabis profile consist of cannabinoids, terpenes, and flavonoids to provide full therapeutic effects against chronic indications such as chronic pain and other neurological indications.

IMCI’s products have standardized and pharma-grade formulations using nanoparticle technology, which improves therapeutic benefits and reduces dosage regimens and side effects.

This enables patients to take smaller doses of active materials and minimize side effects like dysphoria, as the formulation aids in the efficient absorption of cannabinoids into the blood circulation.

IMCI’s first line of products, iCann Relief, includes three products that are designated for chronic pain relief:

iCann Fast, a sublingual tablet with a fast onset of pain relief within 5 to 10 minutes. The tablet dissolves within 60 to 90 seconds after placing it under the patient’s tongue, releasing cannabinoids for about 2.5 hours. The iCann Fast is mostly designated for burst pain during daycare.

iCann LA, is a mucoadhesive tablet, ideal for patients looking to attain relief for the entire day or night, regardless of age. It is easy to consume and administrate against the inner cheek, eliminating the discomfort of swallowing medicines. Its long-acting mechanism, provides therapeutic activity for about eight hours, with the onset after 45 minutes.

Our effective and patient-friendly products are reinventing the medicinal cannabis therapy space by meeting pharma standards, improving patient compliance and their quality of life

iCann Oral is an oral administered capsule with an onset after 20 minutes for a therapeutic activity of pain relief of about three to four hours.

Going beyond physical convenience and benefits, iCann relief products improves a patient’s quality of life with promising therapeutic benefits, including better sleep and appetite and reducestress. Using iCann relief products improves patient experience,compliance and can be used discreetly without the associated social stigma.

Having established a strong footprint in Israel with its agile pharma distribution capabilities, IMCI is open to strategic business collaborations with renowned biopharmaceutical companies in Europe, especially Germany, for global product distribution. Currently, it is reaching the final stages of product development and shifting its focus to commercial manufacturing, with the first line of iCann Relief products to be launched in 2024.

By maintaining a streamlined structure, IMCI ensures that it has the requisite expertise throughout the entire process, from research and development to bringing the product to market.

Developing novel cannabis-based and pharma-grademedicines to affordably treat other prevalent health conditions, IMCI is set to take wings as a provider of choice for scores of biopharmaceutical companies in Europe and around the globe.